

10/571466

Docket No. 285616US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

13 MAR 2006

IN RE APPLICATION OF: Thomas RUECKLE, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/EP04/52143

GAU:

FILED: Herewith

EXAMINER:

FOR: SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Richard L. Treanor

Registration No. 36,379
Corwin P. Umbach, Ph.D.
Registration No. 40,211

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 285616US0PCT		SERIAL NO. New U.S. PCT Application Based on PCT/EP04/52143	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Thomas RUECKLE, et al.			
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	6 335 334	01/01/02	SCHINDLER, Ursula et al.			
	AB	4 927 831	05/22/90	MALAMAS, Michael S.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AJ	1 088 815	04/04/01	EP			NO
	AK	1 088 821	04/04/01	EP			NO
	AL	1 193 267	04/03/02	EP			NO
	AM	1 193 268	04/03/02	EP			NO
	AN	01/23378	04/05/01	WO			NO
	AO	02/28856	04/11/02	WO			NO
	AP	02/26733	04/04/02	WO			NO
	AQ	02/100396	12/19/02	WO			NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AR	RUECKLE, Thomas et al., "Design, synthesis and biological properties of the first generation of novel, potent and selective (Benzoylaminoethyl)-thiophene sulfonamide inhibitors of the c-Jun-N-terminal-Kinase (JNK).", Abstracts of Papers American Chemical Society, Vol. 226, No. 1-2, Page Medi 28, 2003.					
	AS	BENNETT, Brydon L. et al., "JNK: A new therapeutic target for diabetes" Current Opinion in Pharmacology, Vol. 3, No. 4, Pages 420 to 425, 2003.					
	AT	MANNING, Anthony M. et al., "Targeting JNK for therapeutic benefit: from junk to gold? Nature Reviews, Drug Discovery, Vol. 2, No. 7, Pages 554-565, 2003.					
	AU	SCHWEIZER, Ernst H. et al., "Sulfonyliminoimidazolines. A new class of Oral Hypoglycemic Agents. 1. 1-[[p-[2-(Acylamino)ethyl]Phenyl]sulfonyl]-2-iminoimidazolidines", Journal of Medicinal Chemistry, Vol. 26, Pages 964 - 970, 1983.					
	AV	HENQUIN, J.C: "Fifty years of hypoglycaemic sulphonamides", Revue Francaise D'Endocrinologie Clinique-Nutrition ET Metabolisme, Vol. 34, No. 3, Pages 255 to 259, 1993.					
	AW	REAVEN, Gerald M. et al, "Nonketotic Diabetes Mellitus: Insulin Deficiency or Insulin Resistance?, The American Journal of Medicine, Vol. 60, Pages 80 - 88, 1976.					
	AX	STOUT, Robert W. , "Overview of the Association Between Insulin and Atherosclerosis", Metabolism, Vo. 34, No. 12, Pages 7 - 12, 1985					
	AY	DIAMANTI-KANDARAKIS et al., "Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome", Society of the European Journal of Endocrinology, Vol. 138, Pages 269 - 274, 1998.					
	AZ	DUNAIF, Andrea, "Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis", Endocrine Reviews, Vol. 18, No. 6, Pages 774 - 800, 1997.				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

10/571466

New U.S. PCT Application Based on PCT/EP04/52143

Thomas RUECKLE, et al.

Docket No. 285616 US

1AP20 Rec'd PCT/PTO 13 MAR 2006

STATEMENT OF RELEVANCY

- 1) References AA, AJ - AM & AR - AV have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
- 3) References AB, AN - AQ & AW -AZ are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.